The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended six new products during January’s review cycle, including a conditional marketing authorization on re‑examination for a Sanofi asset, according to BioCentury’s data brief. The CHMP actions cover new approvals and regulatory opinions that will now progress toward European Commission decisions. Regulatory teams and European market strategists should note the CHMP’s January cadence and the role that conditional pathways continue to play for accelerated access in the EU. The tally of CHMP opinions also informs launch sequencing and regional commercialization planning.